IL-7

OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression

Retrieved on: 
Wednesday, May 18, 2022
OSE, Transplant, Pharmacokinetics, Health care, Fortification, Autoimmune disease, Immune system, Tissue, IL-7, HCC, Immunotherapy, Inflammation, Teaching hospital, Clinical trial, COVID-19, Large-cell lung carcinoma, Mnemos EP, Boehringer Ingelheim, Nivolumab, Pancreatic cancer, Mab, Growth, Asahi Kasei, GLOBE, Ulcerative colitis, Cancer, Solution, Dialysis, IV, HNSCC, Partnership, Ammonia, Hepatocellular carcinoma, Epitope, ISIN, BI, CD28, Patient, PD-1, SC, IND, Life, Safety, Pharmaceutical industry, Vaccine, Dentistry, Veloxis Pharmaceuticals, Regulatory T cell

NANTES, France, May 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company. VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

Key Points: 
  • VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
  • VEL-101/FR104s prior Phase 1, randomized, double-blind, placebo-controlled study evaluated single and multiple ascending IV doses of VEL-101/FR104 in healthy participants.
  • The current Phase 1 study will provide important data following SC administration before proceeding to studies in the kidney transplant population.
  • We are excited to initiate the development of VEL-101 with this study in healthy participants in the United States.

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT

Retrieved on: 
Monday, May 16, 2022
Engineering, Company, Neoplasm, Private Securities Litigation Reform Act, TILS, Lentivirus, U.S. Securities and Exchange Commission, Survival, EDT, Nasdaq, SPEAR, Sarcoma, OXFORD, PSLRA, CD8, Sumathi Best Television Current Reporting Award, Society, CCL19, Gene, TCR, ADAP, Cell, Growth, Cancer, Security (finance), Annual report, GLOBE, Vaccine, Medical imaging, IL-7

PHILADELPHIA. and OXFORD, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, is presenting preclinical proof-of-concept data from its second next-generation SPEAR T-cell (ADP-A2M4N7X19) targeting MAGE-A4, and novel tumor-infiltrating lymphocytes (TILs) expressing IL-7 (ADP-TILIL7) at the American Society of Gene & Cell Therapy (ASGCT) annual meeting. The Company is presenting the two posters today at 5:30 p.m. EDT during the Cell Therapies I and Targeted Gene and Cell Therapy I sessions.

Key Points: 
  • The Company is presenting the two posters today at 5:30 p.m. EDT during the Cell Therapies I and Targeted Gene and Cell Therapy I sessions.
  • We have now presented preclinical data at ASGCT from our second next-gen therapy designed to improve durability and persistence of SPEAR T-cells that supports clinical investigation.
  • Adaptimmuneis a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer.
  • This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).

OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston

Retrieved on: 
Wednesday, May 11, 2022
Cancer, COVID-19, Epitope, Immune system, Inflammation, Ulcerative colitis, IND, Fortification, INSERM, Pancreatic cancer, Research, Time, Nivolumab, Patient, Immunotherapy, Autoimmune disease, Partnership, Clinical trial, Macrophage, Boehringer Ingelheim, Antigen presentation, OSE, Tissue, IL-7, PD-1, Center, B cell, Mab, Myelocyte, Large-cell lung carcinoma, Vaccine, Fine chemical, Pharmaceutical industry, Transplant

*Collaborative program between OSE Immunotherapeutics and Dr Elise Chiffoleaus ( https://cr2ti.univ-nantes.fr/research/team-1 ) research teams (Center for Research in Transplantation and Translational Immunology (CR2TI), UMR1064, INSERM,Nantes University at Nantes University Hospital).

Key Points: 
  • *Collaborative program between OSE Immunotherapeutics and Dr Elise Chiffoleaus ( https://cr2ti.univ-nantes.fr/research/team-1 ) research teams (Center for Research in Transplantation and Translational Immunology (CR2TI), UMR1064, INSERM,Nantes University at Nantes University Hospital).
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.
  • Other ongoing combination trials sponsored by cooperative clinical research groups in oncology:
    Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
  • OSE-230 (ChemR23 agonist mAb): preclinical stage therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Adaptimmune Reports First Quarter Financial Results and Business Update

Retrieved on: 
Monday, May 9, 2022
ASCO, U.S. Securities and Exchange Commission, EDT, ADAP, Private Securities Litigation Reform Act, IND, Nasdaq, GLOBE, Company, Engineering, Food, Research, Poster, Patient, BLA, Security (finance), CCL19, FDA, Cohort, International, Cancer, Annual report, Conference call, US Foods, IL-7, Synovial sarcoma, R, Center, Exchange, TCR, Genentech, Conference, TILS, G&A, PSLRA, BST, Sumathi Best Television Current Reporting Award, Pharmaceutical industry, Vaccine, Online gambling, Cryptocurrency

- Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) -

Key Points: 
  • - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) -
    PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
  • We remain funded into early 2024 and will continue to execute across these objectives.
  • Adaptimmune is preparing the BLA and targeting submission to the US Food and Drug Administration (FDA) in Q4 2022 for the treatment of synovial sarcoma.
  • After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (6779362).

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

Retrieved on: 
Tuesday, May 3, 2022
Cancer, COVID-19, Head, Epitope, Standard of care, Immune system, Ulcerative colitis, Inflammation, IND, Transplant, Fortification, GLOBE, Mnemos EP, MSS, Pancreatic cancer, Nivolumab, Patient, Immunotherapy, Autoimmune disease, Partnership, Clinical trial, Boehringer Ingelheim, OSE, Tissue, IL-7, ISIN, PD-1, Colorectal cancer, HCC, Disease, Mab, Myelocyte, Large-cell lung carcinoma, Fine chemical, Pharmaceutical industry, Vaccine

Initiation of the Phase 1 clinical expansion trial triggers a 10 million milestone payment from Boehringer Ingelheim to OSE Immunotherapeutics.

Key Points: 
  • Initiation of the Phase 1 clinical expansion trial triggers a 10 million milestone payment from Boehringer Ingelheim to OSE Immunotherapeutics.
  • The trial is being conducted in advanced hepatocellular carcinoma and head and neck cancer patients in combination in particular with anti-PD-1 antibody Ezabenlimab.
  • In particular, a milestone has been achieved upon the first patient dosed in the Phase 1 expansion trial conducted by Boehringer Ingelheim in difficult to treat advanced cancers.
  • Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics, comments: We thank Boehringer Ingelheim for this important new step which demonstrates their commitment and strong belief in the potential of BI 765063 targeting myeloid cells.

OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy

Retrieved on: 
Monday, May 2, 2022
Antibody, PD-1, Boehringer Ingelheim, Antigen presentation, Mab, Patent, IL-7, Immune system, INSERM, T cell, OSE, Fortification, Myelocyte, Large-cell lung carcinoma, Patient, Research, IND, GLOBE, Cancer, Tissue, Pancreatic cancer, COVID-19, Epitope, Partnership, European Patent Convention, Clinical trial, Mnemos EP, Intellectual property, European Patent Office, Center, EPO, Ulcerative colitis, Autoimmune disease, ISIN, Nivolumab, Tumor microenvironment, B cell, Immunotherapy, Inflammation, Pharmaceutical industry, Vaccine, Fine chemical, Transplant

NANTES, France, May 02, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the grant of a new patent from the European Patent Office (EPO) strengthening the protection covering its novel myeloid cell immune checkpoint target, CLEC-1 (a C-type lectin receptor), and its use in cancer treatment.

Key Points: 
  • NANTES, France, May 02, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the grant of a new patent from the European Patent Office (EPO) strengthening the protection covering its novel myeloid cell immune checkpoint target, CLEC-1 (a C-type lectin receptor), and its use in cancer treatment.
  • Myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T-lymphocytes.
  • The patent has been extended to other major territories with the notice of allowance already granted in the United States and the patent granted in Japan.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Infection, IL-7, Immunity, NIT, Industry, Company, Cancer, Vaccine

NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner.

Key Points: 
  • NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner.
  • NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant.
  • NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.
  • The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the Company) that are based on its beliefs and expectations about the future.

Akron BioProducts Announces Launch of its Closed System Solutions™ line to Enable Seamless Integration of cGMP Ancillary Materials in Cell and Gene Therapy Manufacturing

Retrieved on: 
Thursday, April 14, 2022
Research, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Workflow, ISO, MIU, Compliance, Patient safety, New product development, IL-7, Recombinant, Plasma, CSS, CGMP, Safety, FDA, Industry, Rhu, Cytokine, Serum, Vaccine, Fine chemical, Medical device

Akron BioProducts, a leading supplier of cGMP-compliant materials and technologies for cell and gene therapy manufacturing, today announced the launch of its Closed System Solutions (CSS) product line, aimed at functionally closing critical unit operations in cell and gene therapy manufacturing workflows.

Key Points: 
  • Akron BioProducts, a leading supplier of cGMP-compliant materials and technologies for cell and gene therapy manufacturing, today announced the launch of its Closed System Solutions (CSS) product line, aimed at functionally closing critical unit operations in cell and gene therapy manufacturing workflows.
  • Cell and gene therapy developers have long sought to streamline the integration of critical liquid-format cGMP materials into their manufacturing processes.
  • The introduction of our Closed System Solutions line allows for the streamlined delivery of cGMP ancillary materials into the manufacturing process.
  • Akron BioProducts is a leading materials manufacturer and services provider to the cell and gene therapy industry.

NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022

Retrieved on: 
Wednesday, April 13, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Immunity, Association, Moa, Infection, IL-7, Company, American Association for Cancer Research, NIT, American Association, Industry, AACR, Cancer, Pharmaceutical industry, Vaccine

In the two pre-clinical studies presented as posters, NT-I7, a novel long-acting human IL-7, was evaluated in combination with IL-2 (hIL-2/TCB2c), and in combination with anti-TIGIT or anti-VEGF therapies.

Key Points: 
  • In the two pre-clinical studies presented as posters, NT-I7, a novel long-acting human IL-7, was evaluated in combination with IL-2 (hIL-2/TCB2c), and in combination with anti-TIGIT or anti-VEGF therapies.
  • The results of the pre-clinical study showed that the combination of their different mechanisms of action (MoAs) created a heightened anti-tumor response.
  • The pre-clinical results we presented at AACR 2022, which are supported by NT-I7s safety profile and T cell amplifying mechanism, showed the potential for NT-I7 as part of a double or triple-regimen therapy.
  • We are encouraged by these results, which pave the way to advance these combinations in clinical trials, further enhancing NT-I7 clinical value.

Medikine to Highlight Preclinical Data on its Lead Program MDK-703, an IL-7 Mimetic, at the 2022 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Wednesday, April 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Countersurveillance, IL-7, Therapy, Pharmacokinetics, Memory, Survival, Degenerative disease, CD4, Cancer, Poster, Infection, Drug discovery, CD8, Vaccine, Pharmaceutical industry

The poster highlights preclinical data on Medikines lead program MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikines innovative platform technology.

Key Points: 
  • The poster highlights preclinical data on Medikines lead program MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikines innovative platform technology.
  • PEPTIKINES are cytokine receptor agonists that are smaller in molecular size than, and structurally unrelated to, the natural cytokine proteins they emulate.
  • The poster presents data on the effects of MDK-703 on CD8, CD4, and memory T-cell populations in human cells in vitro and when administered to non-human primates and CD34-engrafted humanized mice.
  • Medikine is led by an accomplished team of industry veterans with decades of experience in pioneering drug discovery technology and developing immuno-oncology therapeutics.